ArticleJournal of hypertension2026
Prognostic potential of circulatory miR-19a-3p, miR-19b-3p, and miR-329-3p for future hypertension diagnosis.
Article in Journal of hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs have been suggested as essential hypertension biomarkers, but evidence remains inconclusive due to limited high-throughput studies in population cohorts. We analyzed data from the Young Finns Study (YFS) from 2011 and 2018-2020 to assess cross-sectional and prospective associations between circulatory microRNAs, blood pressure (BP), and hypertension. Hypertension risk prediction potential was assessed using nested logistic and Weibull survival models; model performance was evaluated with likelihood ratio (LR) test and c-statistic. All models were adjusted with relevant risk factors. In 2011, whole blood microRNAs were profiled for 871 individuals (83 with hypertension); in 2018-2020, 760 were re-examined, with 67 newly diagnosed. Cross-sectionally, 16 miRNAs correlated with BP (Spearman, PFDR < 0.05); miR-122-5p (fold change = 1.33) and miR-144-5p (fold change = -1.10) differentiated hypertensive individuals ( U test, PFDR < 0.05). Associations persisted in adjusted regression models and some replicated in LURIC ( n = 999) and YFS serum data ( n = 126). Prospectively, miR-19a-3p [odds ratio (OR) = 1.51, 95% confidence interval (95% CI): 1.14-2.18], miR-19b-3p (OR = 1.50, 95% CI:1.11-2.04), and miR-329-3p (OR = 0.58, 95% CI: 0.39-0.74) levels prognosed hypertension incident. miR-329-3p improved model fit (LR test, P = 2.85×10 -4 ) and discrimination (c-statistic = 0.849, Δ = 0.026). miR-19b-3p predicted time to onset (hazard ratio = 2.13, 95% CI: 1.38-4.45), improving model fit (LR test, P = 0.0012) and time-dependent discrimination at 7 and 8-year horizons. Our findings highlight both novel and previously reported miRNAs associating with BP and hypertension and suggest that miR-329-3p, miR-19a-3p, and miR-19b-3p as promising candidates for further investigation in hypertension risk prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.